Our HIV research agenda has to address the world outside of a clinical trial, vaccine researcher Stephaun E. Wallace, Ph.D., argues.
Anthony J. Santella, Dr.P.H., explains why prevention efforts are lagging within the largest suburban HIV epidemic in the U.S.
A new study demonstrates the phenomenon, but experts say more research needs to determine why it occurs -- and what researchers can do differently to reduce it.
However, a number of leading clinicians argue that the results should not deter care providers from prescribing PrEP for patients who are most at risk for HIV.
Epidemiologists are using a combination of molecular surveillance and tuberculosis-style contact tracing in hopes of helping local health departments curb HIV transmissions.
Project PrIDE demonstration studies in New York and Houston show that properly funded and well-designed outreach programs can impact a city's ability to provide better HIV services for underserved populations.
More than 80 percent of U.S. HIV transmissions in 2016 were from people who were unaware of their status or had been diagnosed but lost to follow-up.
Although people living with HIV who "party and play" appear more likely to struggle with treatment adherence, new research suggests that concern does not apply to PrEP.
As the 2019 National HIV Prevention Conference kicked off on March 18, plenary speakers discussed not only recent biomedical advances, but also what is truly needed in heavily affected U.S. communities to end the epidemic.
"We don't need to spend another $140 million to find out how to retain people in care," activist David Barr writes. "We need to invest in the kinds of services people need so that they can use treatment easily and effectively."